AF
ATRA icon

Amalgamated Financial’s Atara Biotherapeutics ATRA Stock Holding History

Amalgamated Financial’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$100K Buy
+432
New +$138K ﹤0.01% 2145

Other funds holding ATRA

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Amalgamated Financial's ATRA Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Atara Biotherapeutics (ATRA) in Q1 2022: 432 shares worth $100K. The stake represents ﹤0.01% of the portfolio and ranks #2145 among its holdings.

144 funds tracked by Wall St. Rank hold ATRA as of Q1 2022.

  • Amalgamated Financial held 432 shares of Atara Biotherapeutics worth $100K as of Q1 2022.
  • Atara Biotherapeutics was a new Amalgamated Financial position in Q1 2022.
  • Atara Biotherapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2145 holding.
  • 144 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.